Analysts Downgrade Immuneering Corporation Due to Concerns Over Efficacy of IMM1104
Question: Analysts have downgraded Immuneering Corporation (NASDAQ: IMRX) due to concerns over the efficacy of IMM-1-104 in solid tumor trials. ...
Question: Analysts have downgraded Immuneering Corporation (NASDAQ: IMRX) due to concerns over the efficacy of IMM-1-104 in solid tumor trials. ...
Trading of Immuneering shares has come to a sudden stop today, March 14, 2024. This pause was caused by a ...
StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.